A lab-grown micro bladder may explain why urinary tract infections (UTIs) return so frequently, according to a study led by researchers at UCL, the University of Oxford and the University of Leicester.

Parkinson’s disease is expected to cause a substantial economic burden from 2020 to 2040, amounting to 473 billion CNY in constant 2024 prices, which represents 0.017% of projected GDP in China. Utilizing a health-augmented macroeconomic model across 31 provinces, researchers found that disease-induced reductions in physical capital accumulation outweigh labor supply declines in most regions. The findings support tailored prevention and long-term care strategies.

Mr BMT, a most commonly utilized microglia replacement technique, improves microglia engraftment in the central nervous system (CNS) by combining depleting resident microglia and macrophages prior and transplanting bone marrow cells. A recent study assesses the engraftment of peripheral macrophages into recipient mouse models, the gene expression of replaced macrophages and the innate immune response in peripheral organs to establish the safety and durability of the Mr BMT technique.

A new review in Medicine Plus traces a century of deep brain stimulation (DBS), explaining how the therapy alters pathological activity from local circuits to whole-brain networks, and mapping targets and clinical evidence across 16 neurological and psychiatric disorders. It also examines adaptive stimulation, directional leads, and biomarker-guided approaches that could make treatment more precise and personalized.

A new review in Medicine Plus outlines a transformative paradigm for luminal cancers using engineered microbe-based micro/nanorobots. Deployed via oral, suppository, or intracavitary routes, these living platforms bypass physiological barriers, colonize tumor niches, continuously synthesize therapeutics, and remodel the tumor microenvironment. Merging microbial adaptability with synthetic biology, they usher in an era of persistent, spatially controlled intervention.

A new review in Medicine Plus traces the evolution of mRNA lipid nanoparticles (mRNA-LNPs) from prophylactic vaccine vehicles to programmable therapeutic platforms. The authors detail clinical and preclinical progress across infectious disease, cancer, autoimmunity, rare genetic disease and tissue repair, while identifying key translational hurdles including extrahepatic targeting, repeat-dose immunogenicity, off-target editing risks, and scalable manufacturing.